ONCO Onconetix: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Onconetix Corp - graphic logo of issuer ONCO

The market dynamics of the EV/EBITDA multiple, currently 0.00, allow for a valuation of Onconetix, Inc. (ONCO) through the lens of future sales of prostate therapy products. The business is based on the development of diagnostic tools for men's health. An innovative approach to treating hormonal imbalances helps the company avoid price wars with generic manufacturers, effectively protecting its profitability.

Onconetix Corp - ONCO Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/14/2026)

ONCO (onconetix.gcs-web.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Onconetix Corp|ONCO - Average Forecast Price
- company stock capitalization data:
Market Value Onconetix Corporation|ONCO - Company Buyout Price
- book value of equity indicators:
Book Value per Share Onconetix|ONCO - Book Valuation of Business|Market Value to Book Value Ratio onconetix.gcs-web.com|ONCO - Company Total Asset Base
- company liabilities and liquidity data:
Debt to Equity Onconetix, Inc.|ONCO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Onconetix|ONCO - Company Aggregate Debt|Debts to Book Capitalization Onconetix Corporation|ONCO - Company Long-Term Liabilities|Company Short-Term Debt Onconetix|Quick Liquidity onconetix.gcs-web.com
- financial results and valuation multiples details:
ONCO - Company Profit|Projected Future Earnings Onconetix, Inc.|ONCO - Market Cap to Earnings|Projected Price to Earnings Onconetix, Inc.|ONCO - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Onconetix Corporation|ONCO - Operating income before deduction of amortization|Net earnings per share for the last 12 months Onconetix|ONCO - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months onconetix.gcs-web.com|ONCO - Earnings per share increase in current year|Earnings growth forecast for next year Onconetix, Inc.
- sales volume and revenue indicators:
ONCO - Company Gross Revenue|Company Projected Revenue Onconetix Corp|ONCO - Market Cap to Revenue Ratio|Forward P/S Multiple Onconetix Corporation
Fundamental company valuation:Onconetix Corp ONCO
Original product of Onconetix

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest, thereby determining the payback period for capital. For Onconetix, Inc. (ONCO), this calculation is critical, as future sales of targeted prostate cancer therapy will require significant investments in clinic infrastructure. By analyzing the EV/EBITDA trend of Onconetix, Inc. (ONCO), an investor can identify asset value inflection points prior to the drug's market launch.

Competitors of Onconetix, Inc. (ONCO)

Agilent Tech - Enterprise Value to EBITDA Ratio|Quest Corp (DGX) - Company Value to EBITDA|ILMN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio exactsciences.com EXAS|RVTY: EV/EBITDA Multiple|BIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anbio Tech|Nordion (SHC) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QuidelOrtho (QDEL)|OPK - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CareDx Inc CDNA|MRVI: Enterprise Value to Operating Income Before Depreciation|Fulgent Corp - EV/EBITDA Multiple|Standard BioTools Corp (LAB) - Enterprise Value to EBITDA Ratio|Cytek Biosciences, Inc. (CTKB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA orasure.com (OSUR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Exagen Inc|Enterprise Value to Operating Income Before Depreciation MDXH (MDxHealth S.A.)|EV/EBITDA Multiple LUCD|PRE - Company Value to EBITDA|Insight Molecular Diagnostics Inc - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TRIB (Trinity Biotech PLC)|ProPhase Labs - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ainos Inc AIMD|CODX (Co-Diagnostics Corp) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation HSCS|Enterprise Value to EBITDA Ratio BMRA|CDIO: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VRAX|Total Company Value to Operating Income Before Depreciation Ratio Bluejay Diagnostics Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vermillion AWH|AXDX: Enterprise Value to Operating Income Before Depreciation|CENTOGENE, N.V. - EV/EBITDA Multiple|Enzo Biochem, Inc. (ENZ) - Enterprise Value to EBITDA Ratio|FRES (fresh2.co) - Enterprise Value to EBITDA Ratio|GENE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 23andMe Inc.|Company Value to EBITDA Psychemedics Inc PMD